AtheroNova Inc. (AtheroNova), a biotech company focused on the research and development of compounds to regress atherosclerotic plaque, announced that the company has signed a research agreement for their second round of preclinical studies to be conducted at The David Geffen School of Medicine at University of California Los Angeles (UCLA). Diana Shih, PhD, Assistant Professor of Medicine, Department of Cardiology, is the primary investigator for the study.

The study is an adjunct to a preclinical trial being conducted for the company at the Cedars-Sinai Heart Institutes Division of Cardiology. The studies are expected to complete approximately within six months.

AtheroNova, through its wholly-owned subsidiary, AtheroNova Operations, Inc., is a development stage company currently researching novel patents-pending applications of certain natural compounds to regress atherosclerotic plaque deposits, a process called delipidization. The Company plans to develop multiple applications for its compounds, to be used in pharmaceutical grade products for the treatment of atherosclerosis.